Condition
Platelet Refractoriness
Total Trials
6
Recruiting
0
Active
0
Completed
1
Success Rate
25.0%-62% vs avg
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
3 terminated out of 6 trials
Success Rate
25.0%
-61.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
25% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 2 (2)
Trial Status
Terminated3
Unknown2
Completed1
Trial Success Rate
25.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05091684Phase 2Terminated
Administration of Fibrinogen Concentrate for Refractory Bleeding
NCT05284032Early Phase 1TerminatedPrimary
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
NCT04631211Phase 2Terminated
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
NCT05542134UnknownPrimary
Platelet Agregation in Patients on ECMO
NCT03408158Not ApplicableCompleted
HPA Antibodies and the Distribution of Antigen and Antibodies
NCT03679858Unknown
Platelet Antisedimentation Rate and Multiplate Exams in Patients on Antiplatelet Therapy and Controls
Showing all 6 trials